GlassScriptPhysician profile
Campbell B Sindel
NPI 1578975181
$14,091.87
in general payments reported to CMS, 2019-2025
41 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $212 · 2021: $616 · 2022: $1,634 · 2023: $5,375 · 2024: $3,551 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,930 · Education: $4,500 · Travel and Lodging: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,929.63 |
| Education | $4,500.00 |
| Travel and Lodging | $837.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,688.04 | 2022-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,800.31 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,524.80 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $889.81 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $539.51 | 2021-2025 | Hyqvia, Cuvitru, Glassia |
| Genentech USA, INC. | $434.64 | 2019-2025 | Xolair |
| Grifols USA, LLC | $412.73 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $374.93 | 2019-2024 | Opsumit |
| United Therapeutics Corporation | $348.55 | 2019-2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $314.95 | 2023-2025 | Dupixent |
| Genzyme Corporation | $163.19 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $133.85 | 2019 | |
| Electromed, INC. | $133.06 | 2024-2025 | Smartvest |
| Sunovion Pharmaceuticals INC. | $132.44 | 2019 | |
| Pfizer INC. | $108.36 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $100.71 | 2019-2020 | |
| Pulmonx Corporation | $95.43 | 2024-2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Olympus America INC. | $91.01 | 2025 | Spiration Valve System |
| Mylan Specialty L.P. | $89.13 | 2021-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $74.45 | 2023 | Purified Cortrophin Gel |
| Insmed, INC. | $72.29 | 2024-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $61.56 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.44 | 2019 | |
| Verona Pharma, INC. | $38.86 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $38.51 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $38.48 | 2020 | |
| Gilead Sciences, INC. | $34.12 | 2019 | |
| Philips North America LLC | $29.87 | 2023 | |
| Blueprint Medicines Corporation | $25.61 | 2024 | Ayvakit |
| Inogen, INC. | $23.76 | 2022-2024 | |
| Ethicon INC. | $23.60 | 2022 | |
| Octapharma USA, INC. | $23.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.48 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $20.93 | 2025 | Neffy |
| Baxter Healthcare | $18.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Kaleo, INC. | $18.75 | 2023 | Auvi-Q |
| Abiomed | $18.45 | 2024 | Impella |
| Tetraphase Pharmaceuticals, INC. | $17.86 | 2020 | |
| Chiesi USA, INC. | $17.00 | 2023 | Cleviprex, Kengreal |
| Amgen INC. | $14.61 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Campbell Sindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.